Dipsulone;Disulone

Annales de Dermatologie et de Venereologie

Volumn 131, Issue 12, 2004, Pages 1062-1073

  Begon, E ^a   Chosidow, O ^b   Wolkenstein, P ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CIMETIDINE; COTRIMOXAZOLE; CYTOCHROME P450; DAPSONE; GLUCOCORTICOID; IMMUNOGLOBULIN A; ISONIAZID; MACROLIDE; METHYLENE BLUE; OMEPRAZOLE; PROBENECID; PYRIMETHAMINE; RIFAMPICIN; SULFADIMIDINE;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGRANULOCYTOSIS; ALOPECIA; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BEHCET DISEASE; BULLOUS DERMATITIS; DERMATITIS; DERMATITIS HERPETIFORMIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; EOSINOPHILIA; ERYTHEMA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GRANULOMA ANNULARE; HEMOLYSIS; HIDRADENITIS; HUMAN; HYPOALBUMINEMIA; INCIDENCE; KAPOSI SARCOMA; LEISHMANIASIS; LEPROSY; LEUKOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; LICHENOID ERUPTION; LIVER TOXICITY; MALARIA; METHEMOGLOBINEMIA; MUCOUS MEMBRANE PEMPHIGOID; NEUROPATHY; NEUROTOXICITY; PANNICULITIS; PEMPHIGUS; PHOTODERMATOSIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PUSTULAR PSORIASIS; PYODERMA GANGRENOSUM; RELAPSING POLYCHONDRITIS; RETINOPATHY; REVIEW; ROSACEA; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; WELLS SYNDROME;

EID: 11344251066     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(04)93842-2     Document Type: Article

References (140)

1. Sulzberger M. Acrodermatitis continua pustulosa (Hallopeau) treated with sulphapyridine. Arch Dermatol Sphylol 1939;40:1019-21.
2. Wozel G, Hackert I. Sulfone - dermatologische Indikationen und Nebenwirkungen in einer Uebersicht. Dermatol Monatsschr 1986;172:513-22.
3. Lorincz A, Pearson R. Sulfapyridine and sulphone drugs in dermatology. Arch Dermatol 1962;85:42-56.
4. Sneddon I, Wilkinson D. Subcorneal pustular dermatosis. Br J Dermatol 1956;68:385-94.
5. Venkatesan K. Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin Pharmacokinet 1989;16:365-86.
6. Lammintausta K, Kangas L, Lammintausta R. The pharmacokinetics of dapsone and acetylated dapsone in serum and saliva. Int J Clin Pharmacol Biopharm 1979;17:159-63.
7. Pieters FA, Zuidema J. The pharmacokinetics of dapsone after oral administration to healthy volunteers. Br J Clin Pharmacol 1986;22:491-4.
8. Ellard G, Gammon PT, Savin JA, Tan RS. Dapsone acetylation in dermatitis herpetiformis. Br J Dermatol 1974;90:441-4.
9. Zuidema J, Hilbers-Modderman E, Merkus F. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299-315.
10. Mirochnick M, Michaels M, Clarke D, Brena A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. J Pediatr 1993;122:806-9.
11. Coleman MD, Pahal KK, Gardiner JM. The effect of acetylation and deacetylation on the disposition of dapsone and monoacetyl dapsone hydroxylamines in human erythrocytes in-vitro. Pharmacol 1996;48:401-6.
12. Bluhm RE, Adedoyin A, McCarver DG, Branch RA. Developpment of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 1999;65:598-605.
13. Mitra AK, Thummel KE, Kalhom TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995;58:556-66.
14. Ellard G. Absorption, metabolism and excretion of di (rho-aminophenyl) sulphone (dapsone) and di (rho-amonophenyl) sulphoxide in man. Br J Pharmacol 1966;26:212-17.
15. Kazmierowski JA, Ross JE, Peizner DS, Wuepper KD. Dermatitis herpetiformis: effects of sulfones and sulfonamides on neutrophil myeloperoxydase-mediated iodination and cytotoxicity. J Clin Immunol 1984;4:56-64.
16. Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxydase and eosinophil peroxydase by dapsone. Biochem Pharmacol 1992;44:553-63.
17. Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenilalanine by sulfones. J Immunol 1986;137:1305-11.
18. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: Inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997;62:827-36.
19. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD. Dapsone supresses integrin mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40.
20. Coleman MD, Smith JK, Perris AD, Buck NS, Seydel JK. Studies on the inhibitory effects of analogues of dapsone on neutrophil function in-vitro. J Pharm Pharmacol 1997;49:53-7.
21. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 1978;62:214-20.
22. Mier PD, van der Hurk JJ. Ihibition of lysosomal enzymes by dapsone. Br J Dermatol 1975;93:471-2.
23. 4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Inflamm Res 1997;46:420-2.
24. Wozel G, Lehmann B. Dapsone inhibits the generation of 5 lipooxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995;8:196-202.
25. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993;100:349-55.
26. Lang PG Jr. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979;1:479-92.
27. Uetrecht J. Dapsone and sulfapyridine. Clin Dermatol 1989;7:111-20.
28. Bonnetblanc JM. Quelles sont les indications des agents anti-inflammatoires non stéroïdiens en dermatologie? Ann Dermatol Venereol 1999;126:649-52.
29. Costello M. Sulfapyridine in the treatment of dermatitis herpetiformis. Arch Dermatol Syphilol 1947;56:614-24.
30. Fine JD. Management of acquired bullous diseases. N Engl J Med 1995;333:1475-84.
31. Leonard J, Fry L. Treatment and management of dermatitis herpetiformis. Clin Dermatol 1991;9:403-8.
32. Tauber J, Sainz-de-la-Maza M, Foster C. Systemic chemotherapy for ocular pemphigoid. Cornea 1991;10:185-95.
33. rd, Seehafer JR, Perry HO Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982;6:215-23.
34. Ciarocca K, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Radiol Endotol 1999;88:159-63.
35. Rogers RS, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988;7:201-5.
36. Pulimood S, Ajithkumar K, Jacob M, George S, Chandi SM. Linear IgA bullous dermatosis of childhood: treatment with dapsone and co-trimoxazole. Clin Exp Dermatol 1997;22:90-1.
37. Chorzelski TP, Jablonska S, Maciejowska E. Linear IgA bullous dermatosis of adults. Clin Dermatol 1991;9:383-92.
38. Niimi Y, Kawana S, Kusunoki T. IgA pemphigus: A case report and its characteristic clinical features compared with subcorneal pustular dermatosis. J Am Acad Dermatol 2000;43:546-49.
39. Hodak E, David M, Ingber A, Rotem A, Hazaz B, Shamai-Lubovitz O et al. The clinical and histopathological spectrum of IgA-pemphigus: report of two cases. Clin Exp Dermatol 1990;15:433-7.
40. Ongenae KC, Temmerman LJ, Vermander F, Naeyaert JM. Intercellular IgA dermatosis. Eur J Dermatol 1999;9:85-94.
41. Wallach D. Intraepidermal IgA pustulosis. J Am Acad Dermatol 1992; 27:993-1000.
42. Sneddon I, Wilkinson D. Subcorneal pustular dermatosis. Br J Dermatol 1956;68:385-94.
43. Katz SI, Gallin JI, Hertz KC, Fauci AS, Lawley TI. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore) 1977;56:443-55.
44. Yiannias JA, el-Azhary RA, Gibson LE. Erythema elevatum diutinum: a clinical and histopathologic study of 13 patients. J Am Acad Dermatol 1992;26:38-44.
45. Wilkinson SM, English JSC, Smith NP et al. Erythema elevatum diutinum: a clinical and histopathologic study. Clin Exp Dermatol 1992;17:87-93.
46. Grabbe J, Haas N, Moller A, Henz BM. Erythema elevatum diutinum-evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol 2000;143:415-20.
47. Rook A, Waddington E. Pemphigus and pemphigoïd. Br J Dermatol 1953;65:425-31.
48. Venning VA, Millard PR, Wojnarowska F. Dapsone as the first line treatment of bullous pemphigoïd. Br J Dermatol 1989;120:83-92.
49. Bouscarat F, Chosidow O, Picard-Dahan C, Sakiz V, Crickx B, Prost C et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996;34:683-4.
50. rd. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977;113:610-5.
51. rd, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989;14:132-6.
52. Basset N, Guillot B, Michel B, Meynadier J, Guillhou JJ. Dapsone as initial treatment of superficial pemphigus; Report of nine cases. Arch Dermatol 1987;123:783-5.
53. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984; 120:941-52.
54. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20 year review of 107 patients treated with corticosteroids. Arch Dermatol 1976;112:962-70.
55. Huilgol S, Black M. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995;20:283-93.
56. Espagne E, Prost C, Janssen F, Andre C, Flageul B, Vignon MD, Revuz J, Roujeau JC. Epidermolyse bulleuse acquise de l'enfant. Ann Dermatol Venereol 1990;117:814-6.
57. Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hinter H. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1996;34:331-5.
58. Mohr C, Sunderkotter C, Hildebrand A, Biel K, Rutter A, Rutter G. Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins. Br J Dermatol 1995;132:824-6.
59. Lorincz A, Pearson R. Sulfapyridine and sulfone type drugs in dermatology. Arch Dermatol 1962;85:42-54.
60. Fukuhara K, Urano Y, Kimura S, Hori K, Arase S. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 1998;139:556-8.
61. Brown RE, Lay L, Graham D. Bilateral pyoderma gangrenosum of the hand treatment with dapsone. J Hand Surg 1993;18:119-21.
62. Vignon-Pennamen MD, Wallach D. Infantile acropustulosis. A clinico-pathologic study of six cases. Arch Dermatol 1986;122:1155-60.
63. Callen JP. Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 1994;12:201-6.
64. Ruzicka T, Goerz G. Dapsone in the treatment of lupus erythematosus. Br J Dermatol 1981;104:53-6.
65. Coburn PR, Shuster S. Dapsone and discoid lupus erythematosus. Br J Dermatol 1982;106:105-6.
66. Fenton DA, Black MM. Low dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986;11:102-3.
67. McCormack L, Elgart M, Turner ML. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984;11:397-401.
68. Lindkov R, Reymann F. Dapsone in the treatment of cutanous lupus erythematosus. Dermatologica 1986;172:214-7.
69. Tsutsui K, Imai T, Hatta N, Sakai H, Takata M, Takehara K. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996;35:313-5.
70. Holtman JH, Neustadt DH, Klein J, Callen JP. Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. J Rheumatol 1990; 17:1222-5.
71. Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of systemic lupus erytmetatosus with acute, subacute and chronic cutaneous lesions succesfully treated with dapsone. Lupus 1999;8:240-3.
72. Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis. A case report. Angiology 1997;48:1019-22.
73. Fortson JS, Zone JJ, Hammond ME, Groggel GC. Hypocomplementemic urticarial vasculitis syndrome repsonsive to dapsone. J Am Acad Dermatol 1986;15:1137-42.
74. O'Loughlin S, Schreter A, Jordon R. Chronic urticaria-like lesions in systemic lupus erythematosus. A review of 12 cases. Arch Dermatol 1978;114:879-83.
75. Matthews CN, Saihan EM, Warin RP. Urticaria-like lesions associated with systemic lupus erythematosus: response to dapsone. Br J Dermatol 1978;455-7.
76. Ruzicka T, Goerz G. Systemic lupus erythematosus and vasculitis urticaria. Effect of dapsone and complement levels. Dermatologica 1981;162:203-5.
77. Burrows M, Bhogal B, Black M, Rustin M, Ishida-Yamamoto A, Kirtsching G. Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases. Br J Dermatol 1993;128:332-8.
78. Yamada Y, Dekio S, Jidoi J, Ozasa S. Lupus erythematosus profundus: report of a case treated with dapsone. J Dermatol 1989;16:379-82.
79. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987;16:772-8.
80. Ling TC, Kendra JR, Al-Dawoud A, Coulson IH. Lichenoid vasculitis associated with myeloproliferative disorder: successful treatment with dapsone. Br J Dermatol 2001;145:359-60.
81. Nurnberg W, Grabbe J, Czarnetzki BM. Synergistic effets of pentoxyfylline and dapsone in leucoclastic vasculitis. Lancet 1994;343:491.
82. Guillevin L. Treatment of polyarteritis nodosa with dapsone. Scand J Rheumatol 1986;15:95-6.
83. Gillis TP, Williams DL. Dapsone resistance in Mycobacterium leprae. Lepr Rev 2000;71 Suppl:S91-5.
84. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998;27:191-204.
85. Lang T, Greenwood B. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis 2003;3:162-8.
86. rd, Muller SA. Treatment of actnomycetoma with dapsone. Arch Dermatol 1974;109:529-34.
87. Osorio LE, Palacios R, Chica ME, Ochoa MT. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 1998;351:498-9.
88. Dogra J, Lal BB, Misra SN. Dapsone in the treatment of cutaneous leismaniasis. Int J Dermatol 1986;25:398-400.
89. Benedetti-Bardet C, Guy C, Boudignat O, Regnier-Zerbib A, Ollagnier M. Effets secondaires de la Disulone: résultats de l'enquête française de pharmacovigilance. Centre régionaux de pharmacovigilance. Thérapie 2001;56:295-9.
90. Coleman M, Coleman N. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996;14:394-405.
91. Reilly TP, Woster PM, Svensson CK. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions. J Pharmacol Exp Ther 1999;288:951-9.
92. Byrd SR, Gelber RH, Effect of dapsone on haemoglobin concentration in patients with leprosy. Lepr Rev 1991;62:171-8.
93. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia. Drug Metab Rev 1995;27:107-24.
94. Pettit J, Chin J. Does G6PD deficiency modify the course of leprosy and its treatment? Lepr Rev 1964;35:149.
95. Cox NH. Vitamin E for dapsone induced headhache. Br J Dermatol 2002;146:74.
96. Waldinger TP, Siegle RJ, Weber W, Voorhees JJ. Dapsone-induced peripheral neuropathy. Case report and review. Arch Dermatol 1984; 120:356-9.
97. Ahrens E, Meckler R, Callen J. Dapsone induced peripheral neuropathy. Int J Dermatol 1985;25:314-6.
98. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001;162:53-60.
99. Ognibene AJ. Agranulocytosis due to dapsone. Ann Intern Med 1970; 72:521-4.
100. Hornsten P, Keisu M, Wiholm BE The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990;126:919-22.
101. Stern RS. Systemic dapsone. Arch Dermatol 1993;129:301-3.
102. Prussick R, Shear N. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996;35:346-9.
103. Stone SP, Goodwin RM. Dapsone-induced jaundice. Arch Dermatol 1978;114:947.
104. Pertel P Hirsctchick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis 1994;18:630-2.
105. Katoch K, Ramu G, Ramanathan U. Toxic epidermal necrolysis (Lyell syndrome). A case report. Lepr India 1983;55:133-5.
106. Stockel S, Meurer M, Wozel G. Dapsone induced photodermatitis in a patient with linear IgA dermatosis. Eur J Dermatol 2001;11:50-3.
107. Fine JD, Katz SI, Donahue MT, Hendricks AA. Psychiatric reactions to dapsone and sulfapyridine. J Am Acad Dermatol 1983;9:274-5.
108. Daneshmend T. Idiosyncratic dapsone induced manic depression. Br Med J 1989;299:324.
109. Gawkrodger D. Manic depression induced by dapsone in a patient with dermatitis herpetiformis. Br Med J 1989;299:860.
110. Foster PN, Swan CH Dapsone and fatal hypoalbuminaemia. Lancet 1979;2:806-7.
111. Hoffbrand BI. Dapsone and renal papillary necrosis. Br Med J 1978;1:78.
112. Jaffuel D, Lebel B, Hillaire-Buys D, Pene J, Godard P, Michel FB et al. Eosinophilic pneumonia induced by dapsone Br Med J 1998;18:317:181.
113. Seo MS, Yoon KC, Park YG. Dapsonemaculopathy. Korean J Ophthalmol 1997;11:70-3.
114. Grticiute L, Tomatis L. Carcinogenicity of dapsone of mice and rats. Int J Cancer 1980;25:123-9.
115. Sanders SW, Zone JJ, Foltz RC, Tolman KG, Rollins DE. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med 1982;96:465-6.
116. Coleman MD, Scott AK, Brekenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 1990;30:761-7.
117. Coleman MD, Rhodes LE, Scott AK, Verbov JL, Friedmann PS, Breckenbrige AM et al. The use of Cimetidine to reduce dapsone dependent methemoglobinemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 1992;34:244-9.
118. Rhodes LE, Tingle MD, Park BK, Chu P, Verbov JL, Friedmann PS. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995;132:257-62.
119. Kelly JW, Scoot J, Sandland M, Van der Weyden MB, Marks R. Vitamin E and dapsone induced hemolysis, Arch Dermatol 1984;120:1582-4.
120. Prussick R, Ali MA, Rosenthal D, Guyatt G. The protective effect of Vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992;128:210-3.
121. Yu HJ, Park JW, Park JM, Hwang DK, Park YW. A case of childhood generalized pustular psoriasis treated with dapsone. J Dermatol 2001;28:316-9.
122. Smith K, Pittelkow M, Su W. Panniculitis associated with severe alpha 1 antitrypsin deficiency: treatment and review of the litterature. Arch Dermatol 1987;123:1655-61.
123. Proenca NG, Muller H. Weber-Christian panniculitis treated with sulfone. Report of 2 cases. AMB Rev Assoc Med Bras 1981;27:309-12.
124. Saied N, Schwartz RA, Estes SA. Treatment of generalized granuloma annulare with dapsone. Arch Dermatol 1980;116:1345-6.
125. Guill MA, Aton JK. Facial granuloma responsive to dapsone therapy. Arch Dermatol 1982;118:332-5.
126. Kumar B, Kaur I, Bhattacharya M. Dapsone in lichen planus. Acta Derm Venereol 1994;74:334.
127. Kubba RK, Stewart TW. Follicular mucinosis responding to dapsone. Br J dermatol 1974;91:217-20.
128. Hofer T, Itin PH. Acne inversa: a dapsone-sensitive dermatosis. Hautarzt 2001;52:989-92.
129. Cohen JB. Cutaneous involvement of dermato myositis can respond to Dapsone therapy. Int J Dermatol 2002;41:182-4.
130. Krause MH, Torricelli R, Kundig T, Trueb RM, Hafner J. Dapsone in granulomatous rosacea. Hautarzt 1997;48:246-8.
131. Mahendran R, Grant JW, Morris PG Dapsone-responsive persistent erythema multiforme. Dermatology 2000;200:281-2.
132. Kunte C, Loeser C, Wolff H. Folliculitis spinulosa decalvans: successful therapy with dapsone. J Am Acad Dermatol 1998;39:891-3.
133. el Sherif AI, Bharija SC, Belhaj MS, Singh G. Dapsone in Sweet syndrome. Int J Dermatol 1990;29:737.
134. Shear NH, Knowles SR, Shapiro L, Poldre P etal. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1996;35:819-22.
135. Prendiville JS, Logan RA, Russel-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Br J Dermatol 1988;13:67-71.
136. Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad dermatol 1988;18:105-14.
137. Malanin G, Helander I. Eosinophilic pustular foliiculitis (Ofuji's disease): response to dapsone but not to isotretinoin therapy. J Am Acad Dermatol 1989;20:1121.
138. Barranco V, Minor DD, Soloman H. Treatment of relapsing polychondritis with dapsone. Arch Dermatol 1976;112:1286-8.
139. Sharquie KE. Suppression of Behcet disease with dapsone. Br J Dermatol 1984;110:493-4.
140. De Haas E, de Wit RF, van Vollten WP. Non-HIV-related Kaposi's sarcoma suppressed by dapsone. Br J Dermatol 1996;135:813-4.